Literature DB >> 34077562

Neutralizing interferon-α blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.

Xuewei Ding1,2, Wei Xiang3, Ren Yi1,4, Xiaoyan Huang3, Qiuyu Lin3, Xiaojie He1,2.   

Abstract

Plasmacytoid dendritic cells (pDCs) play a key role in the initiation and amplification of systemic lupus erythematosus (SLE)-associated vascular injury. In this study, we found that dsDNA induced dose- and time-dependent increase in IFN-α and Toll-like receptor 7 (TLR7), TLR9 and IRF7 expression in pDCs. Co-cultured circulating endothelial cells (ECs) with activated pDCs significantly decreased proliferation, tube formation and migration in ECs. The elevated level of cellular IFN-α increased cell adhesion, promoted cell apoptosis, induced cell senescence and arrested cells at G0/G1 phase of endothelial progenitor cells (EPCs). Additionally, the co-culture system activated MAPK and inactivated PI3K. Pristane was used to establish a in vivo SLE-like mouse model. Importantly, we showed that INF-α-neutralizing antibody (IFN-α-NA) rescued all the changes induced by IFN-α in vitro and prevented vascular injury in pristane-induced SLE model in vivo. In conclusion, we confirmed that activated pDCs promoted vascular damage and the dysfunction of ECs/EPCs via IFN-α production. IFN-α-neutralizing antibody may be a clinical implication for preventing vascular injury. PI3K signalling and AMPK signalling were associated with SLE-associated vascular functions.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  endothelial cells; endothelial progenitor cells; plasmacytoid dendritic cells; systemic lupus erythematosus; type I interferon

Mesh:

Substances:

Year:  2021        PMID: 34077562      PMCID: PMC8442239          DOI: 10.1111/imm.13379

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.215


  45 in total

1.  Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling.

Authors:  Yu-Jung Wu; Yung-Hsuan Wu; Shu-Ting Mo; Huey-Wen Hsiao; You-Wen He; Ming-Zong Lai
Journal:  J Immunol       Date:  2015-08-03       Impact factor: 5.422

2.  Essential role of ICAM-1 in aldosterone-induced atherosclerosis.

Authors:  Vincenzo Marzolla; Andrea Armani; Caterina Mammi; Mary E Moss; Vittoria Pagliarini; Laura Pontecorvo; Antonella Antelmi; Andrea Fabbri; Giuseppe Rosano; Iris Z Jaffe; Massimiliano Caprio
Journal:  Int J Cardiol       Date:  2017-01-05       Impact factor: 4.164

Review 3.  Anti-interferon alpha treatment in SLE.

Authors:  Kyriakos A Kirou; Elena Gkrouzman
Journal:  Clin Immunol       Date:  2013-03-01       Impact factor: 3.969

4.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 5.  Murine models of systemic lupus erythematosus.

Authors:  Daniel Perry; Allison Sang; Yiming Yin; Ying-Yi Zheng; Laurence Morel
Journal:  J Biomed Biotechnol       Date:  2011-02-14

6.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

7.  Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.

Authors:  Richard Furie; Munther Khamashta; Joan T Merrill; Victoria P Werth; Kenneth Kalunian; Philip Brohawn; Gabor G Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

8.  Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.

Authors:  Kei Sakata; Shingo Nakayamada; Yusuke Miyazaki; Satoshi Kubo; Akina Ishii; Kazuhisa Nakano; Yoshiya Tanaka
Journal:  Front Immunol       Date:  2018-08-28       Impact factor: 7.561

9.  TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.

Authors:  Pui Y Lee; Yutaro Kumagai; Yi Li; Osamu Takeuchi; Hideo Yoshida; Jason Weinstein; Erinn S Kellner; Dina Nacionales; Tolga Barker; Kindra Kelly-Scumpia; Nico van Rooijen; Himanshu Kumar; Taro Kawai; Minoru Satoh; Shizuo Akira; Westley H Reeves
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

10.  Chlorella sorokiniana-Induced Activation and Maturation of Human Monocyte-Derived Dendritic Cells through NF-κB and PI3K/MAPK Pathways.

Authors:  Nien-Tzu Chou; Chieh-Fang Cheng; Hsin-Chieh Wu; Chin-Pen Lai; Li-Tsen Lin; I-Horng Pan; Ching-Huai Ko
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-25       Impact factor: 2.629

View more
  3 in total

1.  Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus.

Authors:  Holly Ryan; Laurence Morel; Erika Moore
Journal:  Front Cardiovasc Med       Date:  2022-03-28

Review 2.  Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment.

Authors:  Kyriakos A Kirou; Maria Dall Era; Cynthia Aranow; Hans-Joachim Anders
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

3.  Neutralizing interferon-α blocks inflammation-mediated vascular injury via PI3K and AMPK in systemic lupus erythematosus.

Authors:  Xuewei Ding; Wei Xiang; Ren Yi; Xiaoyan Huang; Qiuyu Lin; Xiaojie He
Journal:  Immunology       Date:  2021-06-20       Impact factor: 7.215

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.